Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Stimulant

or [[:Category:Antioxidants|Antioxidant]]

or dissociative

Use the filters below to narrow your results.

None (59) · Benzedrex (1) · DXM (1) · DXO (1) · Generic; huge OTC presence (1) · Generic; many OTC formulations (1) · Spravato (1)

Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · None (3) · NMDA antagonist (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist; sigma receptor agonist (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

None (62) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"' (1) · '"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"' (1)

None (62) · General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula) (1)

None (62) · 100, 200, 400 IU softgels and capsules; many proprietary OTC blends; combined formulations (AREDS-2) (1) · 100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) · 28 mg/device (each dose uses 2 devices) (1)

None (62) · 84 mg per session (1) · UL 1000 mg (~1500 IU natural)/d in adults; routinely exceeded in older AREDS-1 trials (1) · UL 2000 mg/d in adults (1)

None (62) · Intranasal (under direct medical supervision) (1) · IV (1) · Oral (2)

None (62) · Days for symptom improvement in scurvy (1) · Days to weeks for tissue saturation (1) · Within hours of first administration (1)

None (62) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Hours (1) · Weeks (fat-soluble) (1)

None (62) · ~10-20 days (steady-state body pool); single dose plasma ~2 hours (1) · ~3-4 days plasma; adipose tissue stores last months (1) · ~7-12 hours (1)

None (62) · High with fat-containing meal; reduced in malabsorption (1) · ~48% intranasal (1) · ~70-90% at typical doses; saturable at high doses (>500 mg) (1)

None (62) · Avoid; may cause fetal harm (1) · Safe at replacement doses; high-dose use generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Safe at routine doses; routinely supplemented in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (62) · OTC in US (2) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 65 results in range #1 to #65.

2

3

4

A

B

Bromantane

C

D

E

H

Hexedrone

I

M

N

O

O-PCE

P

R

RTI-111

S

T

V

Vitamin E

X

Xenon

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"